On July 27th 2023, the “Roche Diagnostics Integrated Innovation Seminar” hosted by Roche Diagnostics—the global leader in in-vitro diagnosis—concluded successfully in Shanghai. The conference focused on the topic of “patient-centered, precision diagnosis driving innovative drug development,” delved into various aspects. These aspects included tumor companion diagnostics, innovative research and development of cancer biomarkers with high medical value, and the opportunities and challenges faced by the commercial clinical laboratories in the future. Simultaneously, the conference concentrated on the progress of Roche’s drug development pipeline, strategies and opportunities for registration of companion diagnostic reagents, and practical considerations for synchronized research and development of Roche’s companion diagnosis and innovative drugs.
At the beginning of the conference, Mr. He Pei, Senior Sales Director of Group Customers of Roche Diagnostics China’s Professional and Molecular Diagnostics Division, took the stage to deliver a speech and express gratitude for the industry’s long-standing attention and support towards Roche. He said that the development and innovation of new drugs are inextricably linked with precise diagnosis, the value of which is becoming increasingly prominent.
Dr. Tang Qiusong, the head of Roche China Accelerator, presented an exposition of the evolution of Roche’s drug development pipeline. He notably highlighted the innovative progress Roche’s research and development holds in the realm of individualized precision medicine, and showcased Roche’s formidable research prowess across diverse domains of disease treatment.
Ms. Yin Qiman, Vice President of Roche Diagnostics China – Medical Regulatory Affairs Department, offered a comprehensive discourse on the strategies and opportunities concerning the registration of companion diagnostics during the keynote address. Further to this, she dissected the regulatory requirements for the registration of companion diagnostics both domestically and internationally, examined the latest developments in the review system, while concurrently exploring the prevailing challenges and opportunities.
The research and development, as well as innovation of new drugs are indispensably linked to precise diagnostics. The success rate of new drug development equally necessitates the support of precise diagnostics. The forthcoming dialogues between Li Yongmei, who heads national clinical value and business development at Roche Diagnostics China’s Organizational Diagnostics Division, and Yin Fang, the technology training and development expert at Roche Diagnostics China’s Technology Innovation Center, offer an exhaustive elucidation on topics concerning “practice and considerations in the collaborative research and development of Roche’s companion diagnostics and innovative drugs,” and “Roche’s fully-automated scientific staining platform accelerating the research and development of innovative drugs”.
Wang Guan, Data Science Vice President of GenomiCare Biotechnology, was cordially invited to attend the conference and participated in a roundtable discussion to share the insightful experiences of GenomiCare Biotechnology in using innovative technologies like artificial intelligence algorithms to assist in the original research and development of new cancer drugs.
Wang Guan articulated that Roche’s philosophy of “putting patients’ needs first” harmoniously aligns with GenomiCare Biotechnology’s underlying strategy, which is to “initiate with the unmet clinical needs of patients, then conduct starting-point innovation for drug discovery.” On this basis, we will have a long-term good cooperation and both of us will make joint efforts to gradually improve the benefits for patients.
In the subsequent guest dialogue discussion, Wang Guan mentioned: The trend of globally synchronized research and development of Chinese innovative drugs is gradually becoming prominent. Domestic innovative pharmaceutical companies are undisputedly accelerating their layout of global research and development. Although there are a lot of uncertainties oh this track, it is unquestionably the right direction to focus on fulfilling unmet clinical needs through innovative drug development from the ground up.
Unlike most traditional pharmaceutical companies, GenomiCare first starts from the unmet clinical needs in the real world, based on patient-centered real-world data, and integrates a large-scale real-world deep molecular clinical knowledgebase and self-developed patented AI algorithms to discover and validate original drug targets based on known mechanisms or specific clinical needs, combined with data intelligent technology to conduct molecular screening of drugs against targets.
Currently, GenomiCare has achieved substantial results at all stages and has established collaborative relationships with the world’s top 10 multinational pharmaceutical groups, including Roche, Merck, Sanofi, AstraZeneca, and Johnson & Johnson. In addition, GenomiCare is helping domestic and international pharmaceutical and biotechnology companies accelerate the discovery and development of innovative oncology drugs. And all the resulting evidence have been demonstrated in novel biomarker and target identification, mechanism of action study, clinical trial design/prediction, drug combination strategy, fine-tuned patient stratification, and new indications expansion.
Based on innovation and leading the future, GenomiCare will continue to dig deep into the self-established multidimensional knowledge base system, using the Patient-centric Plus mode, combining clinical + molecular mechanistic data and artificial intelligence pharmaceutical algorithms to work with partners to discover and develop innovative original drugs for well-defined clinical patient populations to serve the unmet clinical needs of the domestic and international markets. With a win-win mentality, we will actively work with new drug development companies in the industry to discover and develop original new drugs.